Novartis to present key Phase III data on Rhapsido for chronic urticaria and food allergy at EAACI 2026.

Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentations highlight Rhapsido's efficacy and safety across immune-mediated diseases, with additional Phase II data on food allergy. These findings could offer new treatment options for patients with limited current therapies, advancing Novartis' immunology portfolio.